Our Science - Clarametyx Biosciences

The threat of bacterial biofilms

Bacteria naturally prefer biofilm environments

Slime-like, protected communities of bacteria that shield bacteria from immune or antibiotic attack
Composed of extracellular polymeric substance (EPS) and a scaffolding matrix of extracellular DNA (eDNA) and “linchpin” (red) binding proteins

Biofilms protect bacteria
and drive resistance

Drive antibiotic failure, antibiotic resistance, inflammatory responses, and poor clinical outcomes

Responsible for approximately 80 percent of human bacterial infections
Biofilm-encased bacteria can be up to 1,000 times more resistant to antibiotics than those unprotected by biofilms

The Clarametyx Technology
Therapeutic Approach | Vaccination Approach

Powerful Non-Antibiotic and pathogen-agnostic biologic technology

CMTX-101 (purple) antibodies capture and remove key linchpin proteins (red), resulting in rapid biofilm collapse

Key modes of action:

Immune-enabling: Enables a more efficient immune effector intervention to eliminate disease-causing bacteria
Antibiotic-sensitizing: Enhances the effectiveness of antibiotic activity
Inflammation-suppressing: Decreases biofilm-associated inflammation and reduces inflammatory reaction without impairing immune response

Biofilm collapse
drastically increases
bacterial vulnerability

Antibiotic susceptibility increased by 4 to 8 fold
Antibiotics and innate immune effectors able to access bacteria

Unprotected bacteria
are rapidly destroyed

First line antibiotics and innate immune response more effective
Multi-faceted pro-stewardship benefits reduced potential for development of antibiotic resistance
High potential for cost-effective clinical benefit

Vaccination

Vaccinating Against Biofilms

CMTX-301 vaccination triggers the body to produce an immune response to the linchpin DNABII biofilm proteins that enable biofilm formation

Vaccinating Against Biofilms

CMTX-301 vaccination triggers the body to produce an immune response to the DNABII linchpin proteins

Targeting Biofilm Structure

Antibodies are produced that target the linchpin proteins, destabilizing the biofilm eDNA structural lattice and thus preventing biofilm development

Targeting Biofilm Structure

Antibodies are produced that target the linchpin proteins, destabilizing the biofilm eDNA structural lattice and thus preventing biofilm development

More Effective Interventions

In the absence of biofilm, bacteria remain vulnerable to immune or antibiotic intervention

Increases host clearance of the infection
Reduces potential for bacterial resistance development
Reduces inflammation at infection sites

More Effective Interventions

In the absence of biofilm, bacteria remain vulnerable to immune or antibiotic intervention

Increases host clearance of the infection
Reduces potential for bacterial resistance development
Reduces inflammation at infection sites